Fig. 1: Prevalence analysis and mOS benefit in the biomarker-positive group of MYSTIC for various PD-L1 QCS features. | npj Precision Oncology

Fig. 1: Prevalence analysis and mOS benefit in the biomarker-positive group of MYSTIC for various PD-L1 QCS features.

From: Enhanced patient selection with quantitative continuous scoring of PD-L1 expression for IO treatment in metastatic NSCLC

Fig. 1

Subfigure a depicts the D and subfigure b the D + T arm. The features were applied in their identified configuration (cut-point and threshold) and used for stratification, depicting superior stratification—combining a high mOS with a high prevalence—towards the top right quadrant. In addition to PD-L1 QCS features, the pathologist stratification based on TC scores at 1%, 25% and 50% cut-points are indicated in red. A detailed account of the feature parameters is provided in Supplementary Table 7.

Back to article page